Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Leases (2019 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Current Leases for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 68.65% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 68.65% decrease, with the full-year FY2025 number at $4.0 million, down 68.65% from a year prior.
  • Current Leases was $4.0 million for Q4 2025 at Iovance Biotherapeutics, down from $6.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $12.9 million in Q4 2024 to a low of $4.0 million in Q4 2025.
  • A 3-year average of $9.2 million and a median of $9.5 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: surged 65.82% in 2024, then plummeted 68.65% in 2025.
  • Iovance Biotherapeutics' Current Leases stood at $7.8 million in 2023, then soared by 65.82% to $12.9 million in 2024, then tumbled by 68.65% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Current Leases are $4.0 million (Q4 2025), $6.3 million (Q3 2025), and $7.1 million (Q2 2025).